Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study
ABSTRACT Background Therapy for chronic lymphocytic leukemia (CLL) has shifted from chemoimmunotherapy to targeted agents such as Bruton's tyrosine kinase (BTK) inhibitors and BCL‐2 inhibitors. Approved first‐line options include acalabrutinib, a second‐generation BTK inhibitor, and the fixed‐durati...
Збережено в:
| Автори: | , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2026-06-01
|
| Серія: | Cancer Medicine |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1002/cam4.72022 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|